These results, together with a former report showing that a little-molecule ACKR3 agonist CCX771 displays anxiolytic-like conduct in mice,2 help the idea of targeting ACKR3 as a singular technique to modulate the opioid process, which could open new therapeutic avenues for opioid-related disorde